Key result
Alcohol septal ablation is an effective alternative to surgical myectomy for obstructive hypertrophic cardiomyopathy, providing similar symptom relief and survival but with a higher risk of permanent pacemaker implantation.
Why the study?
Does alcohol septal ablation improve symptoms and reduce LVOT gradient compared to surgical myectomy in patients with obstructive hypertrophic cardiomyopathy?
Does alcohol septal ablation improve symptoms and reduce LVOT gradient compared to surgical myectomy in patients with obstructive hypertrophic cardiomyopathy?
Alcohol septal ablation is a well-established, effective alternative to surgical myectomy for reducing LVOT gradient and alleviating symptoms in obstructive hypertrophic cardiomyopathy.
Supports ASA durability in obstructive HCM; extends RCT evidence for long-term equivalence to myectomy.
Alcohol septal ablation (ASA) has become an alternative to surgical myectomy in obstructive hypertrophic cardiomyopathy since it was first introduced in 1994 by Sigwart. The procedure alleviates symptoms by producing a limited infarction of the upper interventricular septum, resulting in a decrease in left ventricular outflow tract (LVOT) gradient. The technique has been improved over time and the results are comparable with those of myectomy. Initial concerns about long-term outcomes have been largely resolved. In this review, we discuss indications, technical aspects, clinical results and patient selection to ASA.
No takes yet. Share an insight, caveat, or question.
Mateo et al. (2018) conducted a review in Hypertrophic cardiomyopathy. Alcohol septal ablation vs. Surgical myectomy was evaluated. Alcohol septal ablation is an effective alternative to surgical myectomy for obstructive hypertrophic cardiomyopathy, providing similar symptom relief and survival but with a higher risk of permanent pacemaker implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: